基线PSMA PET/CT与CT对转移性去势抵抗性前列腺癌患者223Ra治疗结局的影响
本研究为前瞻性观察性研究(NCT04995614)的二次分析,纳入2017至2020年122例mCRPC患者,按基线影像分为PSMA PET/CT组18例与CT组104例。两组碱性磷酸酶和前列腺特异性抗原反应无显著差异,但CT组总生存期显著短于PSMA PET/CT组(12.4 vs 19.9个月,P=0.038),CT组40.1%患者治疗后检出软组织受累。作者认为PSMA PET/CT可能有助于筛选223Ra治疗获益人群。
要点
- 基线PSMA PET/CT组与CT组生化反应无显著差异。
- CT组总生存期显著短于PSMA PET/CT组(12.4 vs 19.9个月,P=0.038)。
- CT组40.1%患者治疗后检出软组织受累,PSMA PET/CT组为0%。
核心结论
- 基线PSMA PET/CT与CT相比似乎不影响223Ra治疗期间的生化反应。
- CT组总生存期显著更短,最可能原因是该组软组织受累检出不足。
- 作者认为以PSMA PET/CT替代基线CT似乎是筛选223Ra治疗最大获益患者的有价值方法。
研究设计与样本
- 前瞻性观察性研究(NCT04995614)数据的二次分析,患者接受最多6个周期223Ra治疗,回顾性分为基线PSMA PET/CT组或基线CT组。
- 2017至2020年纳入122例mCRPC患者,基线PSMA PET/CT组18例(14.8%),基线CT组104例(85.2%)。
- 所有患者均接受基线骨显像,主要终点为碱性磷酸酶和前列腺特异性抗原反应,次要终点为总生存期和放射学反应。
主要发现
- 两组基线特征均具有可比性,碱性磷酸酶或前列腺特异性抗原反应无显著差异。
- 基线CT组总生存期显著短于基线PSMA PET/CT组(12.4 vs 19.9个月,P=0.038)。
- 基线CT组76例中31例(40.1%)接受治疗后CT并检出淋巴结或内脏转移(软组织受累),基线PSMA PET/CT组接受治疗后PSMA PET/CT或CT的15例中为0例。
- 基线CT组无软组织受累的亚组(46/76)与基线PSMA PET/CT组之间总生存期无显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Imaging before 223Ra-dichloride (223Ra) therapy is crucial for selecting metastatic castration-resistant prostate cancer (mCRPC) patients with bone-only disease. The purpose of this study was to evaluate if baseline prostate-specific membrane antigen (PSMA) PET/CT (bPSMA) versus CT is associated with outcomes of 223Ra therapy. Methods: A secondary analysis of the data of a prospective observational study (NCT04995614) was performed. Patients received a maximum of 6 223Ra cycles and were retrospectively divided into the bPSMA or baseline CT (bCT) groups. All patients received baseline bone scintigraphy. Primary endpoints were alkaline phosphatase and prostate-specific antigen response. Secondary endpoints were overall survival (OS) and radiologic response. Results: Between 2017 and 2020, 122 mCRPC patients were included: 18 (14.8%) in the bPSMA group and 104 (85.2%) in the bCT group. All baseline characteristics were comparable. No significant differences in alkaline phosphatase or prostate-specific antigen response were found. The bCT group showed an OS significantly shorter than that of the bPSMA group (12.4 vs. 19.9 mo, P = 0.038). In 31 of 76 patients (40.1%) in the bCT group who also received posttherapy CT, lymph node or visceral metastases (soft-tissue involvement [STI]) were detected after 223Ra therapy, compared with 0 of 15 patients in the bPSMA group who received posttherapy PSMA PET/CT or CT. No significant difference in OS was found between patients in the bCT or posttherapy CT subgroup without STI (46/76) and the bPSMA group. Conclusion: bPSMA versus CT does not seem to impact biochemical response during 223Ra therapy in mCRPC patients. Nevertheless, patients in the bCT group had a significantly shorter OS, most likely due to underdetection of STI in this group. Therefore, replacing bCT with PSMA PET/CT appears to be a valuable screening method for identifying patients who will benefit most from 223Ra therapy.
引用
- Bosch D, van der Velden KJM, Oving IM, et al. The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of 223Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients. J Nucl Med. 2024. PMID: 38423781. doi:10.2967/jnumed.123.266654
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。